Searching map area
Pembrolizumab
? TBD
Pharmaceutical drug used in cancer treatment
Join to rate
Ratings 0
Nobody has rated this yet. Be the first!
Subject of 6
A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours
scientific article published on 15 October 2018
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors.
scientific article published on 14 May 2015
ATIM-24. INTERIM RESULTS OF A PHASE II MULTICENTER STUDY OF THE CONDITIONALLY REPLICATIVE ONCOLYTIC ADENOVIRUS DNX-2401 WITH PEMBROLIZUMAB (KEYTRUDA) FOR RECURRENT GLIOBLASTOMA; CAPTIVE STUDY (KEYNOTE-192)
Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma
scientific article published on 3 October 2017
The use of pembrolizumab for the treatment of metastatic uveal melanoma
scientific article published on 4 February 2016
Pembrolizumab-induced psoriasis vulgaris successfully treated with apremilast
scientific article published on 01 April 2020
Lists 0
Join to rate
Wikipedia

Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody, more specifically a PD-1 inhibitor, used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. It is administered by slow intravenous injection.

Instance of
type of chemical entity
Subclass of
Chemical compound
References
Wikidata